Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor modelsJ. Sorrentino,J. Bisi, D. Thompson,A. Lai,J. Strum,P. RobertsEUROPEAN JOURNAL OF CANCER(2018)引用 7|浏览12暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要